By Fineline Cube 
Merck & Co., Inc. (MSD, NYSE: MRK) announced that China’s National Medical Products Administration (NMPA) has granted marketing approval for Enflonsia (clesrovimab), a long-acting monoclonal antibody (mAb) indicated for the prevention of lower respiratory tract infections caused by respiratory syncytial virus (RSV) in newborns and infants entering or born during their first RSV season.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Full marketing approval |
| Product | Enflonsia (clesrovimab) |
| Indication | Prevention of RSV lower respiratory tract disease in infants |
| Approval Date | June 15, 2026 |
| Dosing | Single fixed dose, no weight measurement required |
Drug Profile & Mechanism of Action
- Molecule: Long-acting monoclonal antibody (mAb)
- Target: RSV fusion glycoprotein
- Innovation: First and only long-acting RSV mAb in China requiring no body weight measurement
- Mechanism: Induces passive immunity by binding to the RSV fusion glycoprotein, providing direct, rapid, and durable protection
- Administration: Single fixed dose for all infants regardless of body weight
Regulatory Timeline
| Date | Milestone |
|---|---|
| June 2024 | First approved in the US as the first and only single-dose RSV mAb for infants of all body weights |
| April 2025 | Submitted for approval in China with priority review designation |
| May 2025 | MSD withdrew the application |
| June 6, 2026 | Resubmitted application |
| June 15, 2026 | Received NMPA approval |
Competitive Landscape
Prior to this approval, nirsevimab from AstraZeneca/Sanofi was the only similar product approved in China for RSV prevention. Enflonsia now becomes the first long-acting RSV monoclonal antibody in the Chinese market that eliminates the need for weight-based dosing calculations, potentially simplifying administration across diverse healthcare settings.
Market Impact & Outlook
- China RSV Burden: RSV represents a significant health burden for infants across China, with seasonal outbreaks causing substantial hospitalizations
- Implementation Advantage: The single-dose, weight-independent administration could streamline implementation in both urban and rural healthcare settings
- Market Position: As the first and currently only long-acting RSV mAb with simplified dosing in China, Enflonsia is positioned to capture significant market share in the infant RSV prevention segment
Forward‑Looking Statements
This brief contains forward-looking statements regarding regulatory approvals and commercial expectations for Enflonsia. Actual results may differ due to risks including market adoption, competitive dynamics, and healthcare policy changes.-Fineline Info & Tech